GoBroad Healthcare Group (高博医疗集团)

GoBroad Healthcare Group (高博医疗集团) is one of China's leading private healthcare groups in advanced cancer treatment research and application, with hospitals and clinics across Beijing, Shanghai, Chongqing and Kunming. GoBroad is especially recognised for CAR-T cell therapy (chimeric antigen receptor T-cell) — an emerging treatment approach for blood and lymphatic cancers that is actively researched here. Beyond CAR-T, GoBroad pioneers clinical trials for novel cancer drugs, checkpoint inhibitor immunotherapy (PD-1/PD-L1) and allogeneic haematopoietic stem cell transplantation. Patients at GoBroad can access specialised research protocols not yet available at conventional hospitals — making it particularly suited for difficult, relapsed or previously treatment-resistant cancers. Expert teams conduct multidisciplinary tumour board reviews and collaborate closely with international research centres. HomeMed provides full support from medical record review and visa application to on-site interpretation and accompaniment. For reference only. Please consult a qualified specialist before making treatment decisions.